TY - JOUR
T1 - Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection
T2 - A meta-analysis of 4 cohorts in the US epidemic
AU - Lim, Jean K.
AU - Louie, Christine Y.
AU - Glaser, Carol
AU - Jean, Cynthia
AU - Johnson, Bernard
AU - Johnson, Hope
AU - McDermott, David H.
AU - Murphy, Philip M.
N1 - Funding Information:
Received 17 May 2007; accepted 6 July 2007; electronically published 7 January 2008. Potential conflicts of interest: none reported. Presented in part: 2007 Biodefense and Emerging Infectious Diseases Symposium, National Institutes of Health, Bethesda, Maryland, 16 May 2007. Financial support: Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Reprints or correspondence: Dr. Philip M. Murphy, National Institutes of Health, 9000 Rockville Pike, Bldg. 10, Rm. 11N113, Bethesda, MD 20892 ([email protected]).
PY - 2008/1/15
Y1 - 2008/1/15
N2 - West Nile virus (WNV) causes disease in ∼20% of infected humans. We previously reported that homozygosity for CCR5Δ32, a nonfunctional variant of chemokine receptor CCR5, is markedly increased among symptomatic WNV-seropositive patients from Arizona and Colorado. To confirm this, we analyzed cohorts from California and Illinois. An increase in CCR5-deficient subjects was found in both (for California, odds ratio [OR], 4.2 [95% confidence interval {CI}, 1.5-11.9] [P = .004]; for Illinois, OR, 3.1 [95% CI, 0.9 -11.2] [P = .06]). A meta-analysis of all 4 cohorts showed an OR of 4.2 (95% CI, 2.1- 8.3 [P < .0001]). Thus, CCR5 deficiency is a strong and consistent risk factor for symptomatic WNV infection in the United States.
AB - West Nile virus (WNV) causes disease in ∼20% of infected humans. We previously reported that homozygosity for CCR5Δ32, a nonfunctional variant of chemokine receptor CCR5, is markedly increased among symptomatic WNV-seropositive patients from Arizona and Colorado. To confirm this, we analyzed cohorts from California and Illinois. An increase in CCR5-deficient subjects was found in both (for California, odds ratio [OR], 4.2 [95% confidence interval {CI}, 1.5-11.9] [P = .004]; for Illinois, OR, 3.1 [95% CI, 0.9 -11.2] [P = .06]). A meta-analysis of all 4 cohorts showed an OR of 4.2 (95% CI, 2.1- 8.3 [P < .0001]). Thus, CCR5 deficiency is a strong and consistent risk factor for symptomatic WNV infection in the United States.
UR - http://www.scopus.com/inward/record.url?scp=39149133656&partnerID=8YFLogxK
U2 - 10.1086/524691
DO - 10.1086/524691
M3 - Article
C2 - 18179388
AN - SCOPUS:39149133656
SN - 0022-1899
VL - 197
SP - 262
EP - 265
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -